Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Article Type
Facet Toggle
Time Frame
Facet Toggle
CGD NOTES
March 28, 2024
Over the past two decades, China has become a distinctive and increasingly important donor of development assistance for health (DAH). However, little is known about what factors influence China’s priority-setting for DAH. In this study, we provide an updated analysis of trends in the priorities of ...
Blog Post
December 20, 2021
As the year draws to a close, the temptation to claim wisdom from adversity and experience becomes irresistible. We did it last year, by exploring what we learnt while the world burned around us. 2021 was perhaps a marginal improvement: not quite the best of times, but not quite the worst of times, ...
Op-Ed
December 06, 2021
Excuses easily come out of the human mouth. Let us please transfer all the energy spent on the manufacturing of excuses to create ideas for how we’ll get vaccines to Africa. If Africa can’t get the vaccines it needs, perhaps Africa should take a play from the Indonesian playbook during the 2007 avia...
Blog Post
December 02, 2021
Many countries around the world have punished most of the African continent for the scientific discovery of the Omicron variant through the imposition of travel bans. These travel bans are more injury upon the injury of low vaccination in Africa. Even well-intentioned rallying phrases such as “vacci...
Blog Post
October 21, 2021
After buying up the World’s vaccine supply to ensure they can protect their own populations, rich countries have found themselves struggling to use the vaccine surpluses they accumulated. One response has been to donate the spare doses to countries who need them more. This is laudable, and countries...
Blog Post
June 14, 2021
Many rich countries pre-ordered vast quantities of COVID-19 vaccines when they were still in development, enough to vaccinate their countries many times over. What is the right ‘price’ to pay for surplus vaccines, as opposed to those newly purchased? And how much of their value should be count...